Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.
8 Jan, 2022 | 22:36h | UTCCommentaries:
Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist
Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology